Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (March 2024)
11 slides from Novo Nordisk A/s Class B's investor day presentation, Mar 8, 2024
Slide 1: Site Kalundborg
Novo Nordisk® Site Kalundborg Henrik Wulff EVP Product Supply, Quality & IT Michael Hallgren SVP Active Pharmaceutical Ingredients 8 MARCH
Slide 2: Forward-looking statements
3 Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2023 and Form 20-F, which both were filed with the SEC in January 2024 in continuation of the publication of the Annual
Slide 3: Product supply value chain in Novo Nordisk
4 Novo Nordisk® Product supply value chain in Novo Nordisk Research and Manufacturing API Filling / Assembly and Distribution Patients development development production tabletting packaging (cold chain) API: Active pharmaceutical ingredient
Slide 4: API production for diabetes and obesity care situated in Clayton and Kalundborg
5 Novo Nordisk® API production for diabetes and obesity care situated in Clayton and Kalundborg Key strategic API sites API production Site Clayton Fermentation Recovery Purification Site Kalundborg API: Active pharmaceutical ingredient
Slide 5: Expanding global supply from key site in Clayton
6 Novo Nordisk® Expanding global supply from key site in Clayton Site Clayton Manufacturing in North Carolina >1,900 manufacturing employees >50 countries supplied by products from North Carolina >137,000 m2 manufacturing facility footprint 4.5 bUSD CAPEX in manufacturing expansions from 1991-2021 C
Slide 6: Major expansions of the Kalundborg site since last visit on Capital Markets Day 2017
7 Novo Nordisk® Major expansions of the Kalundborg site since last visit on Capital Markets Day 2017 Site Kalundborg around last CMD Site Kalundborg today 1 1.1 million m2 ~1,925 1.6 million m2 ~3,050 1 footprint employees in PS KA footprint employees in PS KA 1Employee numbers refer to PS Kalundbor
Slide 7: Accelerated investments and optimisations have enhanced API output at site Kalundborg
8 Novo Nordisk® Accelerated investments and optimisations have enhanced API output at site Kalundborg Announced investments at Kalundborg have accelerated Site Kalundborg API output has increased since 2001 >3x >8x 60 bDKK 18 bDKK 2000 - 2020 2021 – 2023 Higher productivity through optimisations Mol
Slide 8: Productivity at key insulin facility has improved due to continued process and operation optimisations
9 Novo Nordisk® Productivity at key insulin facility has improved due to continued process and operation optimisations Kalundborg insulin purification facility Improving API output without expanding footprint in facility Accumulated knowledge from 100 years of insulin production Process optimisation
Slide 9: Educational programmes in Kalundborg attract international talents
10 Novo Nordisk® Educational programmes in Kalundborg attract international talents Annual admissions to higher educational programmes in Kalundborg International capabilities in API production # of admissions Biotechnologies / Mechanical 301 145 engineering International recruitment: 66 nationaliti
Slide 10: Novo Nordisk benefits from circular collaboration with partners and established infrastructure in Kalundborg
11 Novo Nordisk® Novo Nordisk benefits from circular collaboration with partners and established infrastructure in Kalundborg Kalundborg symbiosis focuses on sustainability Infrastructure in Kalundborg Highway to Kalundborg finalised by 2028 Local roads to be upgraded to fit future need Public trans
Slide 11: Closing remarks
Novo Nordisk® Closing remarks Novo Nordisk has a global footprint for API production Continued investments and optimisations to enhance API output Focus on infrastructure, capabilities and sustainability